Results from a phase Ia/Ib Study of ESG401, a novel Trop2 antibody-drug conjugate, in patients with different subtypes of metastatic breast cancer

被引：0
|
作者：
Ma, F. [1 ]
Qiu, F. [2 ]
Tong, Z. [3 ]
Wang, J. [4 ]
Shi, Y. [5 ]
Zhang, Y. [2 ,10 ]
Yu, G. [6 ]
Shi, H. [7 ]
Wu, X. [8 ]
Liu, A. [9 ]
Zhang, Y. [2 ,10 ]
Wang, H. [11 ]
Cheng, Y. [12 ]
Yang, H. [13 ]
Li, H. [14 ]
Chang, J. [15 ]
Xing, X. [16 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Med Oncol Dept, Beijing, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Med Oncol, Hangzhou, Zhejiang, Peoples R China
[3] TMUCIH Tianjin Med Univ Canc Inst & Hosp, Dept Breast Canc Pathol, Tianjin, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Med Oncol, Beijing, Peoples R China
[5] TMUCIH Tianjin Med Univ Canc Inst & Hosp, Med Oncol Dept Breast Canc, Tianjin, Peoples R China
[6] Weifang Peoples Hosp, Med Oncol, Weifang, Peoples R China
[7] Gannan Med Univ, Affiliated Hosp 1, Med Oncol, Ganzhou, Peoples R China
[8] Hubei Canc Hosp, Mammary Ctr, Wuhan, Peoples R China
[9] Nanchang Univ, Affiliated Hosp 2, Med Oncol, Nanchang, Jiangxi, Peoples R China
[10] Beijing Hosp, Med Oncol, Beijing, Peoples R China
[11] Nanchang Med Coll, Nanchang Peoples Hosp, Breast Oncol Dept, Nanchang, Jiangxi, Peoples R China
[12] Jilin Canc Hosp, Med Oncol, Changchun, Jilin, Peoples R China
[13] Hebei Univ, Affiliated Hosp, Med Oncol, Baoding, Peoples R China
[14] Peking Univ Canc Hosp & Inst, Breast Med, Beijing, Peoples R China
[15] Guizhou Med Univ, Affiliated Hosp, Breast Oncol Dept, Guiyang, Guizhou, Peoples R China
[16] Shanghai Escugen Biotechnol Co Ltd, Clin Dev Dept, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.297
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
349MO
引用
收藏
页码：S361 / S362
页数：2
相关论文
共 50 条
  • [31] Therapy of Advanced Metastatic Lung Cancers with an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132: Interim Phase II Clinical Results
    Camidge, D. R.
    Starodub, Aleander N.
    Ocean, Allyson
    Messersmith, Wells A.
    Bardia, Aditya
    Thomas, Sajeve S.
    Masters, Gregory
    Heist, Rebecca
    Maliakal, Pius
    Govindan, Serengulam
    Sharkey, Robert M.
    Wilhelm, Francois E.
    Goldenberg, David M.
    Guarino, Michael J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S173 - S173
  • [32] Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial
    Bardia, A.
    Juric, D.
    Shimizu, T.
    Tolcher, A.
    Karim, R.
    Spira, A.
    Mukohara, T.
    Lisberg, A. E.
    Kogawa, T.
    Krop, I.
    Papadopoulos, K. P.
    Hamilton, E.
    Damodaran, S.
    Greenberg, J.
    Gu, W.
    Kobayashi, F.
    Guevara, F.
    Jikoh, T.
    Kawasaki, Y.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S60 - S60
  • [33] Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer
    O'Malley, D.
    Richardson, D.
    Vergote, I. B.
    Gilbert, L.
    Martin, L. P.
    Mantia-Smaldone, G. M.
    Castro, C.
    Provencher, D.
    Matulonis, U. A.
    Malek, K.
    Moore, K. N.
    ANNALS OF ONCOLOGY, 2019, 30
  • [34] IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study
    Lemech, C.
    Sun, Y.
    Nagrial, A.
    Wu, X.
    Morris, M.
    Ning, F.
    Yang, J.
    Pan, Y.
    Cai, J.
    Lu, P.
    Zhang, T.
    Qiu, F.
    Hu, C.
    Zhang, M.
    Liu, Z.
    Han, G.
    Nie, J.
    Teng, C.
    Zhou, H.
    Day, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S360 - S360
  • [35] A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
    Gentry T. King
    Keith D. Eaton
    Brandon R. Beagle
    Christopher J. Zopf
    Gilbert Y. Wong
    Heike I. Krupka
    Steven Y. Hua
    Wells A. Messersmith
    Anthony B. El-Khoueiry
    Investigational New Drugs, 2018, 36 : 836 - 847
  • [36] Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.
    Bardia, Aditya
    Diamond, Jennifer Robinson
    Messersmith, Wells A.
    Mayer, Ingrid A.
    Isakoff, Steven J.
    Abramson, Vandana Gupta
    Berlin, Jordan
    Starodub, Alexander
    O'Shaughnessy, Joyce
    Kalinsky, Kevin
    Moroose, Rebecca L.
    Shah, Nikita C.
    Juric, Dejan
    Shapiro, Geoffrey
    Guarino, Michael J.
    Ocean, Allyson J.
    Wilhelm, Francois
    Sharkey, Robert M.
    Goldenberg, David M.
    Vahdat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
  • [37] Phase 2 study of sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate (ADC), in patients with pretreated metastatic small-cell lung cancer (mSCLC)
    Gray, Jhanelle E.
    Heist, Rebecca S.
    Starodub, Alexander N.
    Camidge, D. Ross
    Kio, Ebenezer
    Masters, Gregory
    Purcell, W. Thomas
    Guarino, Michael J.
    Misleh, Jamal
    Schneider, Charles J.
    Schneider, Bryan J.
    Ocean, Allyson J.
    Johnson, Tirrell
    Gandhi, Leena
    Kalinsky, Kevin
    Govindan, Serengulam V.
    Maliakal, Pius
    Mudenda, Boyd
    Wegener, William A.
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2017, 77
  • [38] An open-label, dose-escalation phase I study to evaluate RC48-ADC, a novel antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer
    Wang, Jiayu
    Xu, Binghe
    Wang, Wenxiang
    Fang, Jianmin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
    King, Gentry T.
    Eaton, Keith D.
    Beagle, Brandon R.
    Zopf, Christopher J.
    Wong, Gilbert Y.
    Krupka, Heike I.
    Hua, Steven Y.
    Messersmith, Wells A.
    El-Khoueiry, Anthony B.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 836 - 847
  • [40] Association between stomatitis and treatment efficacy with novel TROP2-directed antibody drug conjugate (ADC), datopotamab deruxtecan, in patients with metastatic cancer
    Abelman, Rachel O.
    Spring, Laura M.
    Ryan, Phoebe K.
    Fell, Geoffrey
    Juric, Dejan
    Heist, Rebecca S.
    Bardia, Aditya
    CANCER RESEARCH, 2023, 83 (07)
12345